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Abstract: Twenty-four new hybrid analogues (15–38) containing 7-chloro-4-aminoquinoline and
2-pyrazoline N-heterocyclic fragments were synthesized. Twelve of the new compounds were
evaluated against 58 human cancer cell lines by the U.S. National Cancer Institute (NCI).
Compounds 25, 30, 31, 36, and 37 showed significant cytostatic activity, with the most outstanding
GI50 values ranging from 0.05 to 0.95 µM. The hybrid compounds (15–38) were also evaluated for
antifungal activity against Candida albicans and Cryptococcus neoformans. From the obtained results
some structure–activity relationships were outlined.
Keywords: cyclocondensation reaction; chalcones; N-aryl-2-pyrazolines; antifungal; antiproliferative
activity
1. Introduction
The substituted 2-pyrazoline moiety (II, Scheme 1) represents a structural component of significant
interest in the field of Medicinal Chemistry, due to their prominent pharmacological effects, such as
antimicrobial, antimycobacterial, antifungal, antiamoebic, anti-inflammatory, analgesic, antidepressant,
and anticancer activities [1–3]. Compounds with this moiety also possess other biological properties
like Nitric Oxide Synthase (NOS) inhibition and Cannabinoid CB1 receptor antagonism, among
others [4].
On the other hand, structure–activity relationship studies on 4-aminoquinolines showed that
the 7-chloro-4-aminoquinoline nucleus (I, Scheme 1) that is present in pharmacologically active
substances displays a broad range of biological activities [5–8]. Therefore, the incorporation of
this active pharmacophore into the structure of new heterocyclic compounds might improve their
biological activity.
Based on the above considerations and as a part of our current project devoted to the synthesis
of novel nitrogen-containing heterocyclic compounds with biological activity [9–13], we decided to
attempt the synthesis of hybrid compounds composed of both the 7-chloro-4-aminoquinoline nucleus
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and the substituted 2-pyrazoline moiety in a single structure (15–38, Scheme 1) looking for compounds
with significant biological activities.
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Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) due to the fact that 
the moiety 2-pyrazoline [11,12] has demonstrated antitumor activities. Furthermore, considering that 
several antineoplastic compounds have proven valuable antifungal activities [14,15], we tested them 
as antifungals against two clinically important fungi, Candida albicans and Cryptococcus neoformans. It is 
important to take into account the limited number of efficacious antifungal drugs, which are not 
completely effective for the eradication of mycoses. There is, therefore, an urgent need for new 
antifungal chemical structures as alternatives to the existing ones [16]. 
2. Results and Discussion 
2.1. Chemistry 
The α,β-unsaturated carbonyl compounds 1–12 were prepared using a previously reported 
methodology (Scheme 2) [15]. These compounds were used as starting materials for the synthesis of 
the target products 15–38 (Scheme 2) of varied structures (15–38) that were obtained in good yields, 
as shown in Table 1. 
 
Scheme 2. General scheme for the synthesis of new N-phenyl and N-4-chlorophenylpyrazolines 
15–38 (methodology previously described in full in [15]). 
Table 1. Synthesis of pyrazolines (15–38) via cyclocondensation reactions. 





15 (90) 16 (92) 17 (83) 18 (77) 19 (76) 20 (86) 
21 (80) 22 (87) 23 (73) 24 (67) 25 (63) 26 (70) 
27 (83) 28 (81) 29 (73) 30 (68) 31 (65) 32 (72) 
33 (75) 34 (71) 35 (61) 36 (47) 37 (53) 38 (60) 
Schem 1. Designed synthetic strategy for the pre aration of the target compounds 15–38. Within
struct res, I represents the starting material with t e 7-chloro-4-aminoquinoline ucleus and II is the
desired product with t e 2-pyrazoline moiety.
The synthesized compound were tested against an ample panel of cancer cell lines within the
Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) due to the fact that
the moiety 2-pyrazoline [11,12] has demonstrated antitumor activities. Furthermore, considering that
several antineoplastic compounds have proven valuable antifungal activities [14,15], we tested them
as antifungals against two clinically important fungi, Candida albicans and Cryptococcus neoformans.
It is important to take into account the limited number of efficacious antifungal drugs, which are
not completely effective for the eradication of ycoses. There is, therefore, an urgent need for new
antifungal chemical structures as alternatives to the existing ones [16].
2. Results and Discussion
2.1. Chemistry
The α,β-unsaturated carbonyl compounds 1–12 were prepared using a previously reported
methodology (Scheme 2) [15]. These compounds were used as starting materials for the synthesis of
the target products 15–38 (Scheme 2) of varied structures (15–38) that were obtained in good yields, as
shown in Table 1.
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Even though the precursors 1–12 for the synthesis of these pyrazolines are very similar, different
reaction conditions had to be used for the synthesis of each particular series, as shown in Scheme 2.
It was observed that the electron density of the substituents on the aryl ring next to the α,β-unsaturated
ketone highly influenced the rates of the cyclocondensation reactions. Electron-donating groups (EDG)
increased the reaction time, while electron-withdrawing groups (EWG) favored the reaction; this may
be due to the fact that EWG increased the electrophilic character of the carbonyl carbon atom, while
the EDG decreased it.
The effective cyclocondensation of the 1,3-dielectrophilic system (C=C-C=O) in compounds 1–12
was confirmed by means of NMR spectroscopy (see Experimental section). For the discussion, we will
take N-phenyl pyrazoline 27 as an example (Figure 1).
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of them correspond to the aromatic protons of the three aryl rings A, C, and D and the H-3 quinoline 
proton between 6.73 and 7.76 ppm; four signals between 7.59 and 8.49 ppm belong to the quinoline 
protons H-2, H-5, H-6, and H-8, and the N-H proton was observed at 9.19 ppm. Additionally, the 26 
magnetically different carbons were found at their respective chemical shifts in the 13C-NMR 
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In addition, the structures of compounds 15–38 were also confirmed through electron impact 
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reported as a mean graph available for analysis by the COMPARE program (data not shown). The 
results of this first assay showed that only compounds 25, 30, 31, 36, and 37 were active. It was 
observed that none of the pyrazolines containing EWG or weakly activating groups like methyl at R 
and R′ position (see Scheme 2) were active in the cancer cell lines. 
The active compounds 25, 30, 31, 36, and 37 passed to a second evaluation step in order to 
determine their cytostatic activity against 58 tumor cell lines of leukemia, melanoma, lung, colon, 
brain, breast, ovary, kidney, and prostate. The results were expressed in the following parameters 
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Figure 1. Structure of co pound 27 sho ing the nu bering of ost carbons.
In the 1H-NMR spectrum (DMSO-d6) of the compound 27, the signals corresponding to the three
chemically and magnetically non-equivalent protons of the pyrazoline ring B appeared as a spin
coupling system AMX. Three double-doublets are observed at 3.13, 3.93, and 5.52 ppm. They belong to
methylenic protons on the diastereotopic center C-41 (HA and HM) and to the methine proton H-51
(HX) of the pyrazoline ring, with coupling constants of 2JAM = 17.4, 3JAX = 6.1 and 3JMX = 12.1 Hz.
Downfield, 13 signals with multiplicity according to their substitution pattern were assigned; eight of
them correspond to the aromatic protons of the three aryl rings A, C, and D and the H-3 quinoline
proton between 6.73 and 7.76 ppm; four signals between 7.59 and 8.49 ppm belong to the quinoline
protons H-2, H-5, H-6, and H-8, and the N-H proton was observed at 9.19 ppm. Additionally, the 26
magnetically different carbons were found at their respective chemical shifts in the 13C-NMR spectrum
of compound 27.
In addition, the structures of compounds 15–38 were also confirmed through electron impact mass
spectrometry (EIMS). The molecular ion peaks (M+¨ ) of all compounds were observed at their respective
molecular mass and the fragmentation pattern was in good agreement with the already reported for
2-pyrazoline derivatives [17]. Furthermore, the molecular ion peak of each compound was found to be
the most stable fragment or base peak in 75% of the synthesized compounds. Mass spectrometry data
on all the synthesized pyrazoline derivatives 15–38 are provided in the Experimental Section.
2.2. Antiproliferative Activity
As a preliminary screening, compounds 15–38 were submitted to the Developmental Therapeutics
Program (DTP) at the National Cancer Institute (NCI) for evaluation of their antiproliferative activity
against different human tumor cell lines. Twelve (16, 18, 19, 22, 24, 25, 28, 30, 31, 34, 36, and 37) of
the submitted compounds were selected and subjected to a preliminary evaluation against 58 tumor
cell lines at a single dose of 10 µM and 48 h of incubation. The output from the single dose screening
was reported as a mean graph available for analysis by the COMPARE program (data not shown).
The results of this first assay showed that only compounds 25, 30, 31, 36, and 37 were active. It was
observed that none of the pyrazolines containing EWG or weakly activating groups like methyl at R
and R1 position (see Scheme 2) were active in the cancer cell lines.
The active compounds 25, 30, 31, 36, and 37 passed to a second evaluation step in order to
determine their cytostatic activity against 58 tumor cell lines of leukemia, melanoma, lung, colon,
brain, breast, ovary, kidney, and prostate. The results were expressed in the following parameters
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according to previously published protocols [18–21]: GI50, which is the molar concentration of the
compounds required to inhibit 50% of the growth of cell lines (relative to untreated cells), and LC50,
which is a parameter of cytotoxicity that reflects the molar concentration needed to kill 50% of the
cells [22]. The active compounds were evaluated at five concentration levels (100, 10, 1.0, 0.1, and
0.01 µM) and the test consisted of a 48-h continuous drug exposure protocol using sulforhodamine
B (SRB) protein assay to estimate cell growth [18–21]. As an interesting result, compounds 25, 30,
31, 36, and 37 exhibited significant cytostatic activity, with GI50 values lower than 1.0 ˆ 10´6 M
against several human cancer cell lines. The biological response elicited by these compounds could be
attributed, in part, to the EDG on ring C (4-OCH3 and 3,4,5-triOCH3). With the exception of compound
31, compounds 30, 36, and 37 were more active (in terms of the average number of cell lines) than
compound 25, which is presumably due to the meta substitution on ring A.
A comparison between the values of GI50 of compounds 25, 30, 31, 36, 37, and the standard
drug (adriamycin) against several tumor cell lines showed that all of these compounds have similar
or even better cytostatic activity than the reference drug, as observed in Table 2. In comparison to
adriamycin (GI50 = 0.12 µM), compound 30 showed better activity against the UACC-62 cell line with
a GI50 = 0.05 µM. Compound 30 was also potent against KAKI-1 (GI50 = 0.68 µM) as compared to
adriamycin (GI50 = 0.95 µM). Interestingly, all of the compounds previously mentioned (25, 30, 31, 36,
37) showed better cytostatic activity than adriamycin (GI50 = 6.46 µM) by a remarkable difference in
GI50 values, going from 0.34 to 2.30 µM against HCT-15 tumor cell line. In Table 2, the compounds that
exhibited promising cytostatic activity against different cell lines are highlighted in gray.
Table 2. In vitro cytotoxic activities of compounds 25, 30, 31, 36, and 37, expressed as growth inhibition
































CCRF-CEM 2.50 >100 0.55 >100 6.40 >100 1.84 >100 4.84 >100 0.08 100.00
HL-60(TB) 4.68 >100 0.28 >100 5.37 >100 4.78 >100 4.18 >100 0.12 89.33
K-562 0.86 >100 0.49 >100 3.75 >100 2.75 >100 0.76 >100 0.19 100.00
MOLT-4 3.86 >100 0.43 >100 7.98 >100 3.18 >100 3.68 >100 0.03 100.00
RPMI-8226 ---- ---- 1.27 99.1 5.33 >100 4.70 >100 3.69 >100 0.08 100.00
SR 1.20 >100 1.17 89.7 5.49 >100 4.29 >100 2.54 >100 0.03 100.00
Non-small Cell Lung
A549/ATCC 4.15 >100 2.00 >100 8.87 >100 4.70 >100 2.72 >100 0.06 100.00
HOP-62 2.14 >100 0.95 >100 3.81 >100 2.44 >100 1.39 >100 0.07 67.61
HOP-92 1.64 >100 3.93 >100 3.60 >100 10.8 >100 1.85 >100 0.10 42.27
NCI-H226 4.77 >100 11.3 >100 41.2 >100 14.2 >100 8.46 >100 0.05 6.40
NCI-H23 8.82 >100 8.78 >100 64.4 >100 17.5 >100 17.5 >100 0.15 13.15
NCI-H322M 13.2 >100 6.39 >100 53.3 >100 15.2 >100 22.2 >100 0.54 67.76
NCI-H460 3.16 >100 0.42 47.0 3.27 >100 3.04 >100 0.77 >100 0.02 51.29
NCI-H522 1.85 >100 0.95 57.0 3.60 >100 4.09 80.8 1.57 >100 0.03 2.80
Colon Cancer
COLO 205 3.28 >100 1.43 48.5 15.7 >100 3.78 >100 3.13 >100 0.18 4.33
HCC-2998 2.09 >100 0.54 47.3 5.32 >100 3.41 80.4 3.14 >100 0.26 21.68
HCT-116 3.08 >100 1.12 43.3 6.51 >100 2.27 56.4 1.68 >100 0.08 54.58
HCT-15 0.88 >100 0.34 57.6 2.91 >100 2.30 >100 1.28 >100 6.46 100.00
HT29 2.66 >100 ---- ---- ---- ---- ---- ---- ---- ---- 0.12 67.45
KM12 1.67 >100 0.23 >100 2.00 >100 0.71 >100 0.82 >100 0.27 92.68
SW-620 2.55 >100 0.28 47.1 2.44 >100 0.53 93.6 0.67 >100 0.09 58.61
CNS Cancer
SF-268 5.49 >100 4.19 >100 75.5 >100 15.5 >100 8.16 >100 0.10 30.48
SF-295 2.02 >100 1.62 60.4 3.55 >100 5.80 65.2 1.71 >100 0.10 69.98
SF-539 1.74 >100 1.15 9.23 3.08 >100 1.80 23.0 1.71 34.2 0.12 27.23
SNB-19 4.91 >100 6.90 >100 >100 >100 15.9 >100 30.3 >100 0.04 49.77
SNB-75 1.11 >100 3.34 >100 6.60 >100 12.5 >100 2.22 >100 0.07 3.30
U251 2.91 >100 ---- ---- ---- ---- ---- ---- ---- ---- 0.04 30.62

































LOX IMVI 1.66 >100 0.34 34.8 2.30 >100 1.30 44.3 0.65 >100 0.07 50.35
MALME-3M >100 >100 10.7 >100 >100 >100 22.7 >100 21.9 >100 0.12 3.97
M14 2.01 >100 0.33 >100 2.60 >100 0.75 47.8 0.63 >100 0.18 4.05
MDA-MB-435 0.33 >100 0.22 >100 1.47 >100 0.72 >100 0.80 >100 0.25 9.57
SK-MEL-2 2.35 >100 2.07 >100 8.78 >100 11.5 >100 4.65 >100 0.17 1.06
SK-MEL-28 2.66 >100 4.41 >100 10.4 >100 7.07 >100 4.54 >100 0.21 15.92
SK-MEL-5 2.68 >100 1.46 18.7 4.56 96.6 3.01 33.4 1.37 18.5 0.08 0.49
UACC-257 2.72 >100 1.36 >100 10.5 >100 6.40 >100 3.45 >100 0.14 8.15
UACC-62 1.17 >100 0.05 54.9 0.87 >100 0.60 54.0 0.31 >100 0.12 0.74
Ovarian Cancer
IGROV1 4.81 >100 11.6 >100 29.2 >100 18.8 >100 3.89 >100 0.17 100.00
OVCAR-3 1.88 >100 3.20 >100 8.64 >100 11.0 >100 3.72 >100 0.39 84.33
OVCAR-5 6.08 >100 11.8 >100 >100 >100 15.6 >100 13.2 >100 0.41 100.00
OVCAR-8 4.19 >100 2.85 >100 7.68 >100 5.00 >100 5.36 >100 0.10 43.25
NCI/ADR-RES 1.70 >100 1.51 >100 5.97 >100 9.51 >100 3.18 >100 7.16 100.00
SK-OV-3 3.26 >100 9.62 >100 >100 >100 15.0 >100 17.3 >100 0.22 100.00
Renal Cancer
786-0 2.88 >100 3.95 >100 5.88 >100 2.94 >100 2.05 >100 0.13 51.64
A498 1.66 >100 2.87 >100 - >100 4.64 >100 4.65 >100 0.10 1.90
ACHN 1.85 >100 3.50 >100 3.52 >100 4.63 >100 1.48 >100 0.08 100.00
CAKI-1 2.12 >100 0.68 >100 2.52 >100 2.38 >100 0.69 >100 0.95 100.00
RXF 393 1.34 >100 8.91 >100 8.37 >100 17.5 >100 2.42 >100 0.10 4.69
SN12C 7.56 >100 7.19 >100 >100 >100 13.0 >100 7.24 >100 0.07 72.44
TK-10 5.05 >100 3.76 >100 9.57 >100 12.9 >100 3.27 >100 0.18 86.70
UO-31 1.58 >100 0.48 >100 1.68 >100 1.87 >100 0.49 >100 0.49 26.18
Prostate Cancer
PC-3 1.47 >100 0.45 >100 1.71 >100 1.18 >100 0.82 >100 0.32 87.10
DU-145 8.08 >100 14.0 >100 >100 >100 28.4 >100 17.1 >100 0.11 100.00
Breast Cancer
MCF7 0.86 >100 1.52 >100 2.74 >100 3.45 >100 2.31 >100 0.03 51.29
MDA-MB-231/ATCC 1.93 >100 1.31 >100 4.77 >100 4.84 >100 2.97 >100 0.51 34.75
HS 578T 2.18 >100 6.79 >100 9.22 >100 14.7 >100 2.45 >100 0.33 85.70
BT-549 2.93 >100 7.42 >100 13.9 >100 2.67 >100 4.63 >100 0.23 21.33
T-47D 2.13 >100 0.17 >100 1.44 >100 0.70 >100 0.69 >100 0.06 85.70
MDA-MB-468 0.91 >100 2.13 >100 20.1 >100 4.45 >100 6.29 >100 0.05 2.52
a Data obtained from NCI’s in vitro disease-oriented human tumor cell lines screen; b GI50 was the drug
concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control
cells during the drug incubation. Determined at five concentration levels (100, 10, 1.0, 0.1, and 0.01 µM); c LC50
a parameter of cytotoxicity and reflects the molar concentration needed to kill 50% of the cells; d The values
of activity against human tumor cell lines displayed by mycin correspond to the reported by NCI at highest
concentration of 10´4 M. Please visit: http://dtp.nci.nih.gov/dtpstandard/cancerscreeningdata/index.jsp. The
most active compounds were highlighted in grey.
2.3. Antifungal Activity
In order to have a look into the potential usefulness of these compounds as candidates for the
developments of new antifungal drugs, we investigated the antifungal properties of compounds
15–38 against two clinically important fungal species, C. neoformans and C. albicans. The selection of
C. neoformans was due to the fact that this opportunistic fungus is the main cause of cryptococcal
meningoencephalitis, which has a high incidence among HIV patients with impaired defenses [23].
High rates of fungal persistence and frequent disease relapse have motivated the search for new
compounds that display antifungal properties against this fungus [24].
Moreover, C. albicans is the fourth leading cause of nosocomial bloodstream infection (BSI) in
intensive care units, causing fatal invasive candidiasis in a high percentage of patients [25]. For this
reason, the development of new potential anticandidal drugs is crucial.
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To assess antifungal activities, the standardized microbroth dilution method M-27A3 for yeasts
of the Clinical and Laboratory Standards Institute was used [26]. Percentages of growth inhibition of
each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL,
which allowed for the determination of MIC100, MIC80, and MIC50.
For a more comprehensive analysis of the results, we grouped all compounds (15–38) into two
series (i, ii) that differ only in the position of the diaryl–azole substituent on the A ring (Table 3):
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; series
(ii) includes compounds 27–38 with the same moiety in the m-position. Each series was sub-divided
into two sub-groups, (i.1) and (ii.1), which comprise compounds with an un-substituted ring D (15–20
and 27–32, respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising.
To gain insight into the structure–activity relationships of the whole series, we compared first
the antifungal behavior of all compounds of series (i) with those of series (ii) against both fungi. We
focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against both
fungi) for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii).
Then, the concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and
<3.9 µg/mL) were analyzed to determine the number of times they were repeated within this series
against both fungi and a percentage of occurrence of each MIC50 value was calculated (respective to
the 24 total MIC50 values obtained in this group). The same analysis was applied to the compounds
in group (ii). With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal
properties of all compounds in series (i) (15–26) and those in series (ii) (27–38) were analyzed against
each fungus separately; these data are presented in Figure 2B,C.
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Figure 2. % Occurrence of each MIC value = number of MICs of each conc/total MICs acting against 
[(A) C. albicans + C. neoformans (Ca + Cn) (24 MIC50 values were considered 100%); (B) C. albicans (12 MIC50 
values were considered 100%); (C) C. neoformans (12 MIC50 values were considered 100%]; (i) includes 
compounds 15–26 with the diaryl-azole moiety in the p-position of ring A; (ii) includes compounds 
27–38 with the same moiety in the m-position. 
As can be seen in Figure 2A, within group (i) 40% of all MIC50 values fall into the value 250 µg/mL, 
while no compounds produced MIC50 values of 7.8 µg/mL or lower. Instead, 21% of the compounds 
within group (ii) fall into the 250 µg/mL concentration, while 4% fall into 7.8 and <3.9 µg/mL. From these 
results, it is clear that compounds of series (ii) exhibit better antifungal properties than those of series 
(i) against both fungi. Regarding the behavior against each fungus separately, series (ii) showed a 
higher percentage of lower MIC50 values over (i) against C. neoformans (Figure 2C). Also, the same trend 
can be observed against C. albicans, where compounds of series (i) showed a much higher percentage of 
MIC50 values at 250 µg/mL than compounds in series (ii). These results indicate that the position of 
the azole moiety does play a role in the antifungal activity and that compounds with this moiety in 
the m-position are better antifungal candidates than those with the azole moiety in the p-position. 
From the previous analyses, it was determined that within the whole series of hybrids of 
N-aryl-substituted pyrazolines with 7-chloro-4-aminoquinoline nucleus tested (15–38), compounds 
of the sub-series (ii.2) with the aryl-azole moiety in m-position of ring A and a p-Cl substituted ring 
D were the most active, mainly against C. neoformans. To corroborate the higher antifungal activity of 
these (ii-2) compounds against C. neoformans over C. albicans, a MIC50 values’ comparison of 33–38 
against both fungi is shown in Figure 3. 
As can be observed in Figure 3, the MIC50 values of compounds 33–38 in C. neoformans are much 
lower than those exhibited by C. albicans, thus suggesting a higher sensitivity of C. neoformans against 
this group of compounds. In this figure, it is evidenced that among the compounds of (ii.2) sub-group, 
compound 36 was by far the most active one, mainly against C. neoformans, and thus it is the best 
anti-cryptococcal candidate of the compounds in this work. 
  
. r f each I value = ber of I s of each conc/ l i i
. albicans + C. neoformans (Ca + Cn) (24 MIC50 values were considered 100%); (B) C. albicans
(12 MIC50 value w considered 100%); (C) C. neoformans (12 MIC50 values were considered 100%];
(i) includes compounds 15–26 with the diaryl-azole moiety n the p-position of ring A; (ii) incl de
compounds 27–38 with the same moiety in the m-position.
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Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the
fungi Candida albicans and Cryptococcus neoformans.
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the determination of MIC100, MIC80, and MIC50. 
For a more comprehensive analysis of the results, we grouped all compounds (15–38) into two 
series (i, ii) that differ only in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; series (ii) 
includes compounds 27–38 with the same moiety in the m-position. Each series was sub-divided into 
two sub-groups, (i.1) and (ii.1), which comprise compounds with an un-substituted ring D (15–20 and 
27–32, respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
l  . tif l ti it  ( I 100, I 80, IC50 values) obtained for co pounds 15–38 a ai st t  
i i  l i    f . 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the determination of MIC100, MIC80, and MIC50. 
For a more comprehensive analysis of the results, we grouped all compounds (15–38) into two 
series (i, ii) that differ only in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; series (ii) 
includes compounds 27–38 with the same moiety in the m-position. Each series was sub-divided into 
two sub-groups, (i.1) and (ii.1), which comprise compounds with an un-substituted ring D (15–20 and 
27–32, respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 250
Cn >250 250 12
16 4
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each f ng s ere fo n  sing all co po n s 15–38 ith a concentration range ithin 250–3.9 g/ , 
hich allo e  for the eter ination of I 100, I 80, an  I 50. 
For a ore co prehensive analysis of the res lts, e gro pe  all co po n s (15–38) into t o 
series (i, ii) that iffer only in the position of the iaryl–azole s bstit ent on the  ring ( able 3): 
series (i) incl es co po n s 15–26 ith the iaryl–azole oiety in the p-position of ring ; series (ii) 
incl es co po n s 27–38 ith the sa e oiety in the -position. ach series as s b- ivi e  into 
t o s b-gro ps, (i.1) an  (ii.1), hich co prise co po n s ith an n-s bstit te  ring  (15–20 an  
27–32, respectively), an  (i.2) an  (ii.2), hich incl e co po n s ith a p- l s bstit te  ring  
(21–26 an  33–38, respectively). able 3 sho s the I 100, I 80, an  I 50 of each co po n . It can 
be observe  that I 50 val es isplaye  by several co po n s (i.e., 25, 32, 36) ere highly pro ising. 
Table 3. ntifungal activity ( I 100, I 80, I 50 values) obtained for co pounds 15–38 against the 
fungi Candida albicans and Cryptococcus neofor ans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 250
Cn >250 250 125
17 4
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which all wed f r the determination of MIC100, MIC80, and MIC50. 
For a more comprehensive analysis of the results, we group d all compounds (15–38) into two
series (i, i that iffer only i  the position of the diaryl–azole substituent on the A ring (Tabl  3):
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; ser es (ii) 
include  compounds 27–38 w th the same moiety in the m-po ition. Each serie  was sub-divided into 
two sub-grou s, ( .1) and (ii.1), which comprise compoun s with an un-substituted ring D (15–20 and 
27–32, respectively) and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifung  a tivity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 25
Cn >250 250 125
18 4
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the determination of IC100, IC80, and IC50. 
For a more comprehensive analysis of the results, we grouped all compounds (15–38) into two 
series (i, ii) that differ only in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; series (ii) 
includes compounds 27–38 with the same moiety in the m-position. Each series was sub-divided into 
two sub-groups, (i.1) and (ii.1), which comprise compounds with an un-substituted ring D (15–20 and 
27–32, respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the IC100, IC80, and IC50 of each compound. It can 
be observed that IC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 250
Cn >250 250 250
19 4
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the determination of MIC100, MIC80, and MIC50. 
For a more comprehensive analysis of the results, we grouped all compounds (15–38) into two 
series (i, ii) that differ only in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole moiety in the p-position of ring A; series (ii) 
includes compounds 27–38 with the same moiety in the m-position. Each series was sub-divided into 
two sub-groups, (i.1) and (ii.1), which comprise compounds with an un-substituted ring D (15–20 and 
27–32, re pectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 62.5
Cn >250 >250 250
20 4
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each fungus were found using all c pounds 5–38 with a concentration range within 250–3.9 µg/ L, 
which allowed for the d t r ination of IC100, IC80, and IC50. 
For a ore co p ehensive analysis f the results, we gr uped all co p unds (15–38) into two 
series (i, ii) that differ nly in the pos ion of the diaryl–az l  substituent on the A ring (Tabl  3): 
series (i) includes co pounds 15–26 with the d ar l–azole oiety i  the p-position of ring A; series (ii) 
includes co pounds 27–38 with t e sa e oi ty in the m-pos ion. Each series was sub-divided into 
two sub-groups, (i.1  and (ii.1), which co prise co pounds with a  un-substituted ring D (15–20 and 
27–3 , respectively), and (i.2) and (ii.2), which include co pounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the IC100, IC80, and IC50 of each co pound. It can 
be observed that IC50 values displayed by several co pounds (i.e., 25, 32, 36) were highly pro ising. 
Table 3. Antifungal activity ( IC100, IC80, IC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




Ca >250 250 250 
Cn >250 250 125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
Ca >250 125 31.2 
Cn >250 250 125 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
Ca 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 125 31.2
Cn >250 250 125
i.2
21 4
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each fungus were foun  using all c mpounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the det rmination of MIC100, MIC80, and MIC50. 
For a more comprehensive analy is of the results, we grouped all compounds (15–38) into two 
i  (i, ii) that differ nly in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole m iety i  the p-position of ring A; series (ii) 
includes c m ounds 27–38 with the sa e moiety in the m-positio . Each series was s b-divided i to 
two sub-groups, (i.1)  (ii.1), which comprise compounds with an un-substituted ring D (15–20 and 
7 32, respectively), and (i.2) and (ii.2), whic  include compou s with a p-Cl substitute  ring D 
(21–26 an  33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




a >250 250 250 
Cn >250 250 125 
16 4 









Ca >250 250 62.5 
Cn >250 >250 250 
20 4 
a  125 31.2
n >250 250 1 5 
i.2 
21 4 
Ca >250 250 62.5 
Cn >250 250 125 
22 4 
Ca >250 >250 250 
Cn >250 250 62.5 
23 4 
Ca >250 62.5 31.2 
Cn >250 250 250 
24 4 
a 250 250 31.2 
Cn >250 >250 >250 
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 250 62.5
Cn >250 250 125
22 4
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each fungus were foun  using all c pounds 15–38 with a concentration range within 250–3.9 µg/ L, 
which allowed for the deter ination of IC100, IC80, and IC50. 
For a ore co prehensive analysis of the r sults, we grouped all co pounds (15–38) into two 
s ri s (i, ii) that differ nly in the position of the diaryl–azole substituent on the A ring (Table 3): 
series (i) includes co pounds 15–26 with the diaryl–azole iety in the p-position of ring A; series (ii) 
includes co ounds 27–38 with the same oiety in the m-positio . Each series was sub-divided i to 
two sub-groups, (i.1)  (ii.1), which co prise co pounds with an un-substituted ring D (15–20 and 
27–32, respectively), and (i.2) and (ii.2), which include co pounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectiv ly). Table 3 shows the IC100, IC80, and IC50 of each co pound. It can 
be observed that IC50 values displayed by several co pounds (i.e., 25, 32, 36) were highly pro ising. 
Table 3. Antifung l activity ( IC100, IC80, IC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




a   250 
n   125 
16 4 
Ca >250 250 0 
Cn >250 250 125 
17 4 
Ca >250 250 0 
Cn >250 250 1 5 
18 4 
Ca >250 250 250 
Cn >250 250 50 
19 4 
a 250 62.5
n >250 250 
20 4 
a 250 125 31.2 






a  >250 250 
n  250 62.5 
23 4 
a 62.5 31.2
n >250 250 
24 4 
a   31.2
n >250 > 0 >250 
25 4 
a 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 >250 250
Cn >250 250 62.5
23 4
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each fungus were found using all compounds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the d t rmination of MIC100, MIC80, and MIC50. 
For a more comp ehens ve analysis f the results, we grouped all compounds (15–38) into two 
series (i, i) that differ only in the pos ion of the diaryl–az l  substituent on the A ring (Table 3): 
series (i) includes compounds 15–26 with the d ar l–azole moiety i  the p-pos tion of ring A; series (ii) 
includes compounds 27–38 with t e same moi ty in the m-pos ion. Each series was sub-divided into 
two sub-groups, (i.1  and (ii.1), which comprise compounds with a  un-substituted ring D (15–20 and 
27–3 , respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observed that MIC50 v lues displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 







a   250 
n   125 
17 4 
a   250 
n   125 
18 4 
a    
n   250 
19 4 
a >250 250 6 .5 
Cn >250 >250 250 
20 4 




a >250 250 62.  
Cn >250 250 125 
22 4 
a >250 > 250 
Cn >250 250 62.5 
23 4 
a >250 6 .5 31.2 
Cn > 250 250 
24 4 
a 250 250 31.2 
n >250 >250 >250 
25 4 
a 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca >250 62.5 31.2
Cn >250 250 250
24 4
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each fungus w re found usi g all com unds 15–38 with a concentration range within 250–3.9 µg/mL, 
which allowed for the determination of MIC100, MIC80, nd MIC50. 
For a m r  co rehen ive analysis of the r sults, we grouped all compou ds (15–38) into two 
series (i, ii) that differ o ly in the positi n f the diaryl–azole substituent on he A ring (Table 3): 
series (i) includes compounds 15–26 with the diaryl–azole moiety i  the p-position of ring A; series (ii) 
includes compounds 27–38 with the same m iety in th  m-position. Each series was sub-divided in o 
two su -g oups, (i.1) and (ii.1), which comprise compounds with  un-substituted ing D (15–20 and 
27–32, respectively), and (i.2) and (ii.2), which in lude compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, an  MIC50 of each compound. I  can 
be observed th t MIC50 v lues isplayed by s ve al compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




a   250 
n   125 
16 4 
a 250
n   125 
17 4 
a   250 
n 125
18 4 
a    
n   250 
19 4 
a 250 62.5
n >250 250 
20 4 
a 125 31.2






a  >250 250 
n  250 62.5 
23 4 
a 62.5 31.2
n >250 250 
24 4 
a 250 250 31.2 
n >250 >250 >250 
25 4 
a 50 25 .  
Cn 62.5 31.2 15.6 
Ca 250 250 31.2
Cn >250 >250 >250
25 4
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eac  fungus were found usi g all compounds 15–38 with a concentration range within 2 0–3.9 µg/mL, 
which allowed for th  d t rmination f MIC100, MIC80, and MIC50. 
For a more comp ehe sive analysis f the results, we gr uped all comp unds (15–38) into two 
series (i, ii) that differ only in the position of the diaryl–az l  substituent on the A ring (Table 3): 
series (i) incl des compounds 15–26 with the diar l–azole oiety in the p-position of ring A; series (ii) 
includes compounds 27–38 with t e same moi ty in the m-positio . Each series wa  sub-divi ed into 
two sub-groups, (i.1) and (ii.1), which comprise compounds with a  un-substituted ring D (15–20 and 
27–3 , respectively), and (i.2) and (ii.2), which include compounds with a p-Cl substituted ring D 
(21–26 and 33–38, respectively). Table 3 shows the MIC100, MIC80, and MIC50 of each compound. It can 
be observ d that MIC50 values displayed by several compounds (i.e., 25, 32, 36) were highly promising. 
Table 3. Antifungal activity (MIC100, MIC80, MIC50 values) obtained for compounds 15–38 against the 
fungi Candida albicans and Cryptococcus neoformans. 
 




a   250 
n   125 
16 4 
Ca >250 250 250 
Cn >250 250 125 
17 4 
Ca >250 250 250 
Cn >250 250 125 
18 4 
Ca >250 250 250 
Cn >250 250 250 
19 4 
a >250 250 6 .5 
n >250 >250 250 
20 4 
a 250 125 31.  
n   1 5 
i.2 
21 4 
a 250 250 62.5 
n 250 250 125 
22 4 
Ca >250 > 250 
Cn >250 250 62.5 
23 4 
a 250 6 .5 31.2 
n >  250 250 
24 4 
a 250 250 31.2 
n >  >250 >250
25 4 
Ca 250 125 15.6 
Cn 62.5 31.2 15.6 
Ca 250 125 15.6
Cn 62.5 31.2 15.6
26 4
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26 4 
Ca >250 >250 250 




Ca 250 125 62.5 
Cn >250 >250 125 
28 3 
Ca >250 250 62.5 
Cn >250 >250 62.5 
29 3 
Ca >250 >250 125 
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To gain insight into the structure–activity relationships of the whole series, we compared first 
the antifungal behavior of all compounds of series (i) with those of series (ii) against both fungi. We 
focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against both fungi) 
for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were analyzed to determine the number of times they were repeated within this series against both 
fungi and a percentage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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To gain insight into the structure–activity relationships of the whole series, we compared first 
the antifungal behavior of all compounds of series (i) with those of series (ii) against both fungi. We 
focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against both fungi) 
for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were analyzed to determine the number of times they were repeated within this series against both 
fungi and a percentage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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To gain insight int  the structure–activity relationships f the whole series, we c mpared first 
the antifu gal behavior of all compounds of series (i) with those of series (ii) against both fungi. We 
f cused on the last column (MIC50) of Table 3. This col mn contains 24 MIC50 values (against bot  fungi) 
f r compou ds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentr tion values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were a alyzed to determine the number of times they were repeated within this series against both 
fungi and a percentage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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To gain insight into the structure–activity relationships of the whole series, we compared first 
the antifu gal behavior of all compounds of series (i) with those of series (ii) against both fungi. We 
focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against bot  fungi) 
for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were analyzed to determine the number of times they were repeated within this series against both 
fungi and a percentage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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To gain insight int  the structure–activity relations ips of the whole series, we compared first 
the antifungal behavior of all compounds of series (i) with those of series (ii) against both fungi. We 
focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against both fungi) 
for compou ds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were a alyzed to determine the number of times they were repeated within this series against both 
fungi and a perce tage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this grou ). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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focused on the last colu n (MIC50) of Table 3. This column contains 24 MIC50 values (against both fungi) 
for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were analyzed to determine the number of times they wer  repeated wit in this series against both 
fungi and a percentage of occurrence of each MIC50 value was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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fungi and a percentage of occurrence of each I 50 value as calculated (respective to the 24 total 
I 50 values obtained in this group). The sa e analysis as applied to the co pounds in group (ii). 
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f cused on the last colu n (MIC50) of Table 3. This column contains 24 MIC50 value (against both fungi)
or compoun s 15–26 of gr up (i), and 24 MIC50 values of com ounds 27–38 of group (ii). Then, the
concentration values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL)
were analyzed to determine the number of times they we re eated wi in this series agains  both
fungi and a percentage of occurrence of each MIC50 val e was calculated (respective to the 24 total 
MIC50 values obtained in this group). The same analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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were analyzed to deter ine the nu ber of ti es they were repe ted within this series against b th
fungi and a percentage of occurrence of each IC50 value w s calculated (respective to the 24 total
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To gain insight nto the structure–activity r lat onships f the whole series, we compared first 
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focused on the last column (MIC50) of Table 3. This column contains 24 MIC50 values (against bot  fungi) 
for compounds 15–26 of group (i), and 24 MIC50 values of compounds 27–38 of group (ii). Then, the 
conc ntr tion values of MIC50 within group (i) (>250, 250, 125, 62.5, 31.2, 15.6. 7.8, 3.9, and <3.9 µg/mL) 
were analyzed to determine the number of times they were repe ted within this seri s against b h 
fungi and a percentage of occu rence of ach MIC50 value w s calculated (respective to the 24 total 
MIC50 values obtained in this group). The ame analysis was applied to the compounds in group (ii). 
With these data, a comparative graph was produced (Figure 2A). Lastly, the antifungal properties of 
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ere an lyzed to deter ine the nu ber of ti es they ere repeated ithin this serie  against both 
fungi and a percentage of occurrence of each IC50 value as calculated (respective to the 24 total 
IC50 values obtained in this group). The sa e analysis as applied to the co pounds in group (ii). 
ith these data, a co parative graph as produced (Figure 2 ). Lastly, the antifungal properties of 
Ca 62.5 62.5 5.6
Cn <3.9 <3.9 <3.9
37 3
Molecules 2016, 21, 969 7 of 19 
 
26 4 
a >250 >250 250 




Ca 0 125 62.5 
Cn >250 >250 125 
28 3 
Ca >250 250 62.5 
Cn >250 >250 62.5 
29 3 
Ca >250 >250 125 
Cn >250 >250 250 
0  
Ca 250 250 125 
 250 250 31.2 
31 3 
Ca >250 >250 250 
Cn >250 >250 250 
32 3 
 62.5 62.5 1 6
Cn 31.2 15.6 7.8 
ii.2 
33 3 
Ca >250 >250 250 
Cn 250 250 62.5 
34 3 
  >250 >250 
Cn >250 250 3 .2 
35 3 
Ca >250 250 125 
Cn >250 250 62.5 
36 3 
 6 .  62.5 15.6 
Cn <3.9 <3.9 <3.9 
37 3 
Ca 125 31.2 31.2 
Cn 125 62.5 31.2 
38 3 
Ca 125 125 62.5 
Cn 125 62.5 62.5 
  
Amphotericin B 
a 1.00 0.50 0.50 
  n 1.25 0.50 0.50 
To ga  insight nto the structure–activ ty r l t onships f the whole series, we compared first 
the antifu gal behavi r of all compounds f ser es (i) with those of series (ii) against both fu gi. We 
focused on the last colu n (MIC50) of Table 3. This column cont ins 24 MIC50 value  (against bot  fungi) 
or compo nds 15–26 of gr up (i), and 24 MIC50 v lues of compounds 27–38 of group (i ). Then, the 
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As can be seen in Figure 2A, within group (i) 40% of all MIC50 values fall into the value 250 µg/mL,
while no compounds produced MIC50 values of 7.8 µg/mL or lower. Instead, 21% of the compounds
within group (ii) fall into the 250 µg/mL concentration, while 4% fall into 7.8 and <3.9 µg/mL.
From these results, it is clear that compounds of series (ii) exhibit better antifungal properties than
those of series (i) against both fungi. Regarding the behavior against each fungus separately, series (ii)
showed a higher percentage of lower MIC50 values over (i) against C. neoformans (Figure 2C). Also, the
same trend can be observed against C. albicans, where compounds of series (i) showed a much higher
percentage of MIC50 values at 250 µg/mL than compounds in series (ii). These results indicate that
the position of the azole moiety does play a role in the antifungal activity and that compounds with
this moiety in the m-position are better antifungal candidates than those with the azole moiety in the
p-position.
From the previous analyses, it was determined that within the whole series of hybrids of
N-aryl-substituted pyrazolines with 7-chloro-4-aminoquinoline nucleus tested (15–38), compounds of
the sub-series (ii.2) with the aryl-azole moiety in m-position of ring A and a p-Cl substituted ring D
were the most active, mainly against C. neoformans. To corroborate the higher antifungal activity of
these (ii-2) compounds against C. neoformans over C. albicans, a MIC50 values’ comparison of 33–38
against both fungi is shown in Figure 3.
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Figure 3. Comparison of MIC50 values of each compound of the (ii.2) sub-series against C. albicans or 
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3. Materials and Methods 
3.1. General Information 
Commercially available starting materials, reagents, and solvents were used as supplied. 
Microwave irradiation reactions were performed in glass vessels (10 mL) using a CEM Discover 
Focused Microwave Synthesis System™ apparatus (Matthews, NC, USA), with power output from 0 
to 300 W. TLC analyses were performed on Merck (EMD Millipore, Billerica, MA, USA) silica gel 60 
F254 aluminum plates. Melting points were determined in a Büchi (Instrumart, South Burlington, 
VT, USA) melting point apparatus and are uncorrected. IR spectra were performed on a Shimadzu 
(Scientific Instruments, Seattle, WA, USA) FTIR 8400 spectrophotometer in KBr disks. The 1H- and 
13C-NMR spectra were run on a Bruker (Karlsruhe, Germany) DPX 400 spectrophotometer operating 
at 400 MHz and 100 MHz respectively, using dimethylsulfoxide-d6 as solvents and tetramethylsilane 
as internal reference. The mass spectra were obtained on a Hewlett Packard (Scientific Instrument 
Services, Ringoes, NJ, USA) HP Engine-5989 spectrometer (equipped with a direct inlet probe) 
operating at 70 eV. The elemental analyses were obtained using a Thermo-Finnigan Flash EA1112 
CHN (Elemental Microanalysis Ltd., (Okehampton, Devon, UK) elemental analyzer. 
3.2. Synthesis 
3.2.1. General Procedure for the Synthesis of the Precursors 1–12 
Using the same previously reported method [15], precursors 1–12 were obtained.  
3.2.2. General Procedure for the Preparation of Compounds 15–20 
A mixture of 4-(7-chloroquinolin-4-yl) amino chalcone 1–6 (0.11 mmol), phenylhydrazine 13 
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Figure 3. Comparison of MIC50 values of each compound of the (ii.2) sub-series against C. albicans or
C. neoformans.
As can be observed in Figure 3, the MIC50 values of compounds 33–38 in C. neoformans are much
lower than those exhibited by C. albicans, thus suggesting a higher sensitivity of C. neoformans against
this group of compounds. In this figure, it is evidenced that among the compounds of (ii.2) sub-group,
compound 36 was by far the most active one, mainly against C. neoformans, and thus it is the best
anti-cryptococcal candidate of the compounds in this work.
3. Materials and Methods
3.1. General Information
Commercially available starting materials, reagents, and solvents were used as supplied.
Microwave irradiation reactions were performed in glass vessels (10 mL) using a CEM Discover
Focused Microwave Synthesis System™ apparatus (Matthews, NC, USA), with power output from 0 to
300 W. TLC analyses were performed on Merck (EMD Millipore, Billerica, MA, USA) silica gel 60 F254
aluminum plates. Melting points were determined in a Büchi (Instrumart, South Burlington, VT, USA)
melting point apparatus and are uncorrected. IR spectra were performed on a Shimadzu (Scientific
Instruments, Seattle, WA, USA) FTIR 8400 spectrophotometer in KBr disks. The 1H- and 13C-NMR
spectra were run on a Bruker (Karlsruhe, Germany) DPX 400 spectrophotometer operating at 400 MHz
and 100 MHz respectively, using dimethylsulfoxide-d6 as solvents and tetramethylsilane as internal
reference. The mass spectra were obtained on a Hewlett Packard (Scientific Instrument Services,
Ringoes, NJ, USA) HP Engine-5989 sp ctromet r (eq ipped with a direct inlet probe) operating at
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70 eV. The elemental analyses were obtained using a Thermo-Finnigan Flash EA1112 CHN (Elemental
Microanalysis Ltd., (Okehampton, Devon, UK) elemental analyzer.
3.2. Synthesis
3.2.1. General Procedure for the Synthesis of the Precursors 1–12
Using the same previously reported method [15], precursors 1–12 were obtained.
3.2.2. General Procedure for the Preparation of Compounds 15–20
A mixture of 4-(7-chloroquinolin-4-yl) amino chalcone 1–6 (0.11 mmol), phenylhydrazine 13
(0.33 mmol) in glacial acetic acid (10 mL) was submitted to microwave irradiation for 12 min at 250 W
and 120 ˝C. Once the reaction mixture was cooled to room temperature, the resulting solution was
neutralized with concentrated ammonium hydroxide. Then, crushed ice was added to the solution
and a solid was precipitated, collected by vacuum filtration, washed thoroughly with water, dried,
and recrystallized from ethanol.
N-(4-(5-(4-Bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine (15).
Yellow solid; 90% yield; mp: 97–99 ˝C. FTIR (KBr) υ(cm´1): 3350 (NH), 3054 (=C-H), 1599 and 1576
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.12 (dd, J = 17.4, 6.1 Hz, 1H, H-41a), 3.92 (dd,
J = 17.4, 12.1 Hz, 1H, H-41b), 5.49 (dd, J = 12.1, 6.1 Hz, 1H, H-51), 6.72 (t, J = 7.6 Hz, 1H, Ar-H), 6.99
(d, J = 7.6 Hz, 2H, Ar-H), 7.07 (d, J = 5.4 Hz, 1H, H-3), 7.12–7.19 (m, 2H, Ar-H), 7.26 (d, J = 8.4 Hz,
2H, Ar-H), 7.41 (d, J = 8.7 Hz, 2H, Ar-H), 7.54 (d, J = 8.4 Hz, 2H, Ar-H), 7.59 (dd, J = 9.1, 2.3 Hz, 1H,
H-6), 7.77 (d, J = 8.7 Hz, 2H, Ar-H), 7.92 (d, J = 2.3 Hz, 1H, H-8), 8.42 (d, J = 9.1 Hz, 1H, H-5), 8.51 (d,
J = 5.4 Hz, 1H, H-2), 9.24 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.3 (CH2), 63.0, 100.0
(C), 103.3, 113.4, 119.1 (C), 119.2, 120.9 (C), 122.2, 125.0, 125.7, 127.4, 127.9 (C), 128.0, 128.7, 129.4, 132.4,
131.9 (C), 134.6 (C), 142.4 (C), 144.6 (C), 147.6 (C), 149.5 (C), 152.0. MS (70 eV) m/z (%): 552 (100, M+),
397 (17), 368 (34), 313 (32), 271 (35), 236 (47), 123 (34), 98 (47), 91 (67), 83 (54), 57 (81), 44 (67). Anal.
Calcd. For C30H22BrClN4: C, 65.05; H, 4.00; N, 10.12. Found: C, 65.20; H, 3.98; N, 10.15.
7-Chloro-N-(4-(5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (16).
Yellow solid; 92% yield; mp: 121–124 ˝C. FTIR (KBr) υ(cm´1): 3263 (NH), 3056 (=C-H), 1597 and 1572
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.09 (dd, J = 17.4, 6.1 Hz, 1H, H-41a), 3.90 (dd,
J = 17.4, 11.9 Hz, 1H, H-41b), 5.48 (dd, J = 11.9, 6.1 Hz, 1H, H-51), 6.71 (t, J = 7.5 Hz, 1H, Ar-H), 6.98 (d,
J = 7.5 Hz, 2H, Ar-H), 7.06 (d, J = 5.1 Hz, 1H, H-3), 7.15 (t, J = 7.5 Hz, 2H, Ar-H), 7.31 (d, J = 8.5 Hz, 2H,
Ar-H), 7.36–7.44 (m, 4H, Ar-H), 7.57 (dd, J = 9.0, 2.1 Hz, 1H, H-6), 7.76 (d, J = 8.5 Hz, 2H, Ar-H), 7.91 (d,
J = 2.1 Hz, 1H, H-8), 8.41 (d, J = 9.0 Hz, 1H, H-5), 8.50 (d, J = 5.1 Hz, 1H, H-2), 9.25 (br s, 1H, NH).
13C-NMR (100 MHz, DMSO-d6) δ ppm 42.9 (CH2), 62.4, 63.1 (C), 102.8, 112.9, 118.6, 121.6, 124.5, 125.2,
126.9, 127.3 (C), 127.6, 127.9, 128.9, 129.0, 131.9 (C), 134.1 (C), 140.9 (C), 141.5 (C), 144.2 (C), 147.1 (C),
147.2 (C), 149.5 (C), 152.0. MS (70 eV) m/z (%): 508 (100, M+), 397 (19), 368 (9), 279 (23), 254 (15), 243
(14), 91 (47), 77 (17). Anal. Calcd. For C30H22Cl2N4: C, 70.73; H, 4.35; N, 11.00. Found: C, 70.79; H,
4.37; N, 10.89.
7-Chloro-N-(4-(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (17). Yellow solid; 83%
yield; mp: 109–111 ˝C. FTIR (KBr) υ(cm´1): 3270 (NH), 3060 (=C-H), 1598 and 1573 (C=N and C=C).
1H-NMR (400 MHz, DMSO-d6) δ ppm 3.11 (dd, J = 17.4, 6.2 Hz, 1H, H-41a), 3.93 (dd, J = 17.4, 12.2 Hz,
1H, H-41b), 5.48 (dd, J = 12.2, 6.2 Hz, 1H, H-51), 6.65–6.73 (m, 2H, Ar-H), 7.00 (d, J = 7.8 Hz, 2H, Ar-H),
7.06–7.18 (m, 3H, Ar-H and H-3), 7.23–7.38 (m, 4H, Ar-H) 7.42 (d, J = 8.6 Hz, 2H, Ar-H), 7.60 (dd, J = 9.1,
2.2 Hz, 1H, H-6), 7.78 (d, J = 8.6 Hz, 2H, Ar-H), 7.92 (d, J = 2.2 Hz, 1H, H-8), 8.43 (d, J = 9.1 Hz, 1H, H-5),
8.52 (d, J = 5.3 Hz, 1H, H-2), 9.27 (s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.6 (CH2), 63.6,
112.5, 113.3, 118.8, 122.1, 125.1, 125.6, 126.4, 127.4, 127.9, 128.2, 129.2, 129.4, 134.5 (C), 141.4 (C), 143.1
(C), 144.8 (C), 147.5 (C), 147.8 (C), 150.0 (C), 150.1 (C), 152.5, 169.5 (C). MS (70 eV) m/z (%): 474 (100,
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M+), 397 (19), 279 (15), 121 (35), 105 (68), 91 (42), 77 (52), 57 (33), 43 (31). Anal. Calcd. For C30H23ClN4:
C, 75.86; H, 4.88; N, 11.80. Found: C, 75.81; H, 4.65; N, 11.73.
7-Chloro-N-(4-(5-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (18) [27].
Yellow solid; 77% yield; mp: 111–112 ˝C. FTIR (KBr) υ(cm´1): 3312 (NH), 3040 (=C-H), 1597 and 1572
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.06 (dd, J = 17.3, 6.2 Hz, 1H, H-41a), 3.70 (s, 3H,
OCH3), 3.87 (dd, J = 17.3, 12.0 Hz, 1H, H-41b), 5.40 (dd, J = 12.0, 6.2 Hz, 1H, H-51), 6.69 (t, J = 7.3 Hz,
1H, Ar-H), 6.88 (d, J = 8.8 Hz, 2H, Ar-H), 7.00 (d, J = 8.0 Hz, 2H, Ar-H), 7.06 (d, J = 5.3 Hz, 1H, H-3),
7.10–7.17 (m, 2H, Ar-H), 7.20 (d, J = 8.5 Hz, 2H, Ar-H), 7.40 (d, J = 8.5 Hz, 2H, Ar-H), 7.57 (dd, J = 9.0,
1.9 Hz, 1H, H-6), 7.76 (d, J = 8.5 Hz, 2H, Ar-H), 7.91 (d, J = 1.9 Hz, 1H, H-8), 8.40 (d, J = 9.0 Hz, 1H, H-5),
8.49 (d, J = 5.3 Hz, 1H, H-2), 9.25 (br, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.5 (CH2), 55.5
(OCH3), 63.1, 103.1, 113.4, 114.5, 114.8, 118.9 (C), 119.0, 122.3, 124.8, 125.8, 127.3, 127.6, 128.2 (C), 129.4,
134.8 (C), 134.9 (C), 141.0 (C), 144.7 (C), 147.4 (C), 148.1 (C), 149.5 (C), 152.3, 158.9 (C). MS (70 eV) m/z
(%): 504 (100, M+), 399 (10), 279 (18), 121 (18), 91 (34), 77 (13), 57 (10). Anal. Calcd. For C31H25ClN4O:
C, 73.73; H, 4.99; N, 11.09. Found: C, 73.42; H, 4.87; N, 11.07.
7-Chloro-N-(4-(1-phenyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine
(19). Yellow solid; 76% yield; mp: 99–102 ˝C. FTIR (KBr) υ(cm´1): 3240 (NH), 3056 (=C-H), 1598 and
1575 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.15 (dd, J = 17.4, 7.3 Hz, 1H, H-41a), 3.63
(s, 3H, OCH3), 3.71 (s, 6H, 2 ˆ OCH3), 3.91 (dd, J = 17.4, 12.1 Hz, 1H, H-41b), 5.34 (dd, J = 12.1, 7.3 Hz,
1H, H-51), 6.64 (s, 2H, Ar-H), 6.74 (t, J = 7.2 Hz, 1H, Ar-H), 7.02–7.10 (m, 3H, Ar-H and H-3), 7.15–7.21
(m, 2H, Ar-H), 7.42 (d, J = 8.8 Hz, 2H, Ar-H), 7.60 (dd, J = 9.1, 2.2 Hz, 1H, H-6), 7.79 (d, J = 8.8 Hz, 2H,
Ar-H), 7.92 (d, J = 2.2 Hz, 1H, H-8), 8.43 (d, J = 9.1 Hz, 1H, H-5), 8.52 (d, J = 5.3 Hz, 1H, H-2), 9.25 (s,
1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.7 (CH2), 56.4 (2 ˆ OCH3), 60.5 (OCH3), 64.4, 103.5,
113.6, 119.2, 120.2 (C), 122.1, 125.1, 125.7, 127.5, 127.9 (C), 128.2 (C), 128.8 (C), 129.4, 132.2, 133.3 (C),
134.6 (C), 137.1, 139.0 (C), 141.4 (C), 145.4 (C), 147.9 (C), 152.4, 153.8 (C). MS (70 eV) m/z (%): 564 (100,
M+), 397 (35), 279 (18), 243 (12), 91 (32), 77 (12). Anal. Calcd. For C33H29ClN4O3: C, 70.14; H, 5.17; N,
9.92. Found: C, 70.09; H, 5.11; N, 9.82.
7-Chloro-N-(4-(1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (20). Yellow solid;
86% yield; mp: 89–92 ˝C. FTIR (KBr) υ(cm´1): 3230 (NH), 3052 (=C-H), 1599 and 1577 (C=N and C=C).
1H-NMR (400 MHz, DMSO-d6) δ ppm 2.25 (s, 3H, CH3), 3.07 (dd, J = 17.3, 6.3 Hz, 1H, H-41a), 3.89
(dd, J = 17.3, 12.2 Hz, 1H, H-41b), 5.41 (dd, J = 12.2, 6.3 Hz, 1H, H-51), 6.66–6.72 (m, 1H, Ar-H), 7.00 (d,
J = 7.8 Hz, 2H, Ar-H), 7.07 (d, J = 5.3 Hz, 1H, H-3), 7.11–7.15 (m, 4H, Ar-H), 7.17–7.21 (m, 2H, Ar-H),
7.41 (d, J = 8.6 Hz, 2H, Ar-H), 7.58 (dd, J = 9.0, 2.2 Hz, 1H, H-6), 7.77 (d, J = 8.6 Hz, 2H, Ar-H), 7.92
(d, J = 2.2 Hz, 1H, H-8), 8.43 (d, J = 9.0 Hz, 1H, H-5), 8.51 (d, J = 5.3 Hz, 1H, H-2), 9.24 (s, 1H, NH).
13C-NMR (100 MHz, DMSO-d6) δ ppm 21.2 (CH3), 43.6 (CH2), 63.5, 103.3, 112.6, 113.4, 118.9, 122.1,
125.3, 126.3, 127.3, 128.0 (C), 128.2, 129.2, 130.0, 134.5 (C), 137.0 (C), 140.1 (C), 141.4 (C), 144.5 (C), 147.5
(C), 147.7 (C), 149.9 (C), 150.2 (C), 152.5. MS (70 eV) m/z (%): 488 (11, M+), 368 (31), 236 (47), 210 (61),
150 (60), 108 (100), 97 (49), 83 (60), 69 (56), 43 (39). Anal. Calcd. For C31H25ClN4: C, 76.14; H, 5.15; N,
11.46. Found: C, 76.12; H, 5.09; N, 11.36.
3.2.3. General Procedure for the Preparation of Compounds 21–26
A mixture of the corresponding chalcone 1–6 (0.11 mmol), 4-chlorophenylhydrazine hydrochloride
14 (0.22 mmol), BF3¨OEt2 (0.2 mL, molar excess) as catalyst, and EtOH (8 mL) was heated under reflux
for 7 h. After this time, the product was observed as a precipitate and was filtered and washed three
times with the EtOH/H2O (1:0.5) mixture. No further purification was required.
N-(4-(5-(4-Bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine
(21). Yellow solid; 80% yield; mp: >300 ˝C. FTIR (KBr) υ(cm´1): 3410 (NH), 3020 (=C-H), 1613 and
1589 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.18 (dd, J = 17.5, 5.8 Hz, 1H, H-41a),
3.97 (dd, J = 17.5, 12.1 Hz, 1H, H-41b), 5.59 (dd, J = 12.1, 5.8 Hz, 1H, H-51), 6.94 (d, J = 6.7 Hz, 1H,
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H-3), 7.00 (d, J = 8.9 Hz, 2H, Ar-H), 7.21 (d, J = 8.9 Hz, 2H, Ar-H), 7.30 (d, J = 8.3 Hz, 2H, Ar-H), 7.42
(d, J = 8.3 Hz, 2H, Ar-H), 7.54 (d, J = 8.4 Hz, 2H, Ar-H), 7.84 (dd, J = 9.2, 1.3 Hz, 1H, H-6), 7.89 (d,
J = 8.4 Hz, 2H, Ar-H), 8.16 (d, J = 1.3 Hz, 1H, H-8), 8.55 (d, J = 6.7 Hz, 1H, H-2), 8.86 (d, J = 9.2 Hz, 1H,
H-5), 11.07 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.3 (CH2), 62.9, 101.5, 114.9, 117.0
(C), 120.9, 123.0 (C), 125.2, 126.5, 127.6, 127.7, 128.4, 129.3, 129.6, 130.8 (C), 132.6 (C), 138.3 (C), 138.5 (C),
141.1 (C), 141.4 (C), 143.2 (C), 145.2, 148.0 (C), 154.0 (C). MS (70 eV) m/z (%): 586 (55, M+), 368 (24), 346
(28), 313 (33), 236 (31), 125 (37), 97 (53), 71 (59), 57 (100), 43 (94). Anal. Calcd. For C30H21BrCl2N4: C,
61.25; H, 3.60; N, 9.52. Found: C, 61.15; H, 3.78; N, 9.63.
N-(4-(1,5-bis(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine (22). Yellow
solid; 87% yield; mp: >300 ˝C. FTIR (KBr) υ(cm´1): 3418 (NH), 3025 (=C-H), 1614 and 1569 (C=N and
C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.19 (dd, J = 17.6, 5.7 Hz, 1H, H-41a), 3.97 (dd, J = 17.6,
12.2 Hz, 1H, H-41b), 5.59 (dd, J = 12.2, 5.7 Hz, 1H, H-51), 6.95 (d, J = 6.8 Hz, 1H, H-3), 7.01 (d, J = 8.8 Hz,
2H, Ar-H), 7.21–7.26 (m, 4H, Ar-H), 7.53–7.57 (m, 4H, Ar-H), 7.83–7.96 (m, 3H, Ar-H and H-6), 8.11 (d,
J = 1.4 Hz, 1H, H-8), 8.56 (d, J = 6.8 Hz, 1H, H-2), 8.80 (d, J = 9.2 Hz, 1H, H-5), 11.00 (br s, 1H, NH).
13C-NMR (100 MHz, DMSO-d6) δ ppm 43.3 (CH2), 63.0, 101.3, 114.9, 116.8 (C), 120.4, 121.2 (C), 123.0
(C), 125.5, 126.4, 127.8, 127.9, 128.7, 129.3, 131.1 (C), 132.5, 138.1 (C), 138.8 (C), 140.2 (C), 141.7 (C), 143.1
(C), 144.7, 147.9 (C), 154.6 (C). MS (70 eV) m/z (%): 542 (100, M+), 431 (15), 368 (13), 279 (20), 125 (14).
Anal. Calcd. For C30H21Cl3N4: C, 66.25; H, 3.89; N, 10.30. Found: C, 66.40; H, 4.00; N, 10.52.
7-Chloro-N-(4-(1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (23).
Yellow solid; 73% yield; mp: >300 ˝C. FTIR (KBr) υ(cm´1): 3429 (NH), 3021 (=C-H), 1613 and 1591
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.18 (dd, J = 17.5, 6.0 Hz, 1H, H-41a), 3.98 (dd,
J = 17.5, 12.3 Hz, 1H, H-41b), 5.56 (dd, J = 12.3, 6.0 Hz, 1H, H-51), 6.94 (d, J = 6.8 Hz, 1H, H-3), 7.01 (d,
J = 8.9 Hz, 2H, Ar-H), 7.20 (d, J = 8.9 Hz, 2H, Ar-H), 7.24–7.32 (m, 3H, Ar-H), 7.35 (d, J = 7.2 Hz, 2H,
Ar-H), 7.55 (d, J = 8.4 Hz, 2H, Ar-H), 7.85 (dd, J = 9.0, 1.9 Hz, 1H, H-6), 7.91 (d, J = 8.4 Hz, 2H, Ar-H),
8.16 (d, J = 1.9 Hz, 1H, H-8), 8.55 (d, J = 6.8 Hz, 1H, H-2), 8.90 (d, J = 9.0 Hz, 1H, H-5), 11.17 (br s, 1H,
NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.6 (CH2), 63.7, 101.6, 114.9, 117.1 (C), 121.3, 122.8 (C),
125.0, 126.3, 126.5, 127.5, 127.6, 128.1, 129.2, 129.6, 130.7 (C), 136.4 (C), 138.1 (C), 138.6 (C), 142.5 (C),
143.4 (C), 145.5, 147.9 (C), 153.6 (C). MS (70 eV) m/z (%): 508 (100, M+), 431 (16), 369 (12), 279 (20), 254
(17), 125 (35), 90 (14). Anal. Calcd. For C30H22Cl2N4: C, 70.73; H, 4.35; N, 11.00. Found: C, 70.69; H,
4.42; N, 10.95.
7-Chloro-N-(4-(1-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine
(24). Yellow solid; 67% yield; mp: >300 ˝C. FTIR (KBr) υ(cm´1): 3421 (NH), 2679 (=C-H), 1616 and
1597 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.15 (dd, J = 17.6, 5.8 Hz, 1H, H-41a), 3.72
(s, 3H, OCH3), 3.94 (dd, J = 17.6, 12.1 Hz, 1H, H-41b), 5.51 (dd, J = 12.1, 5.8 Hz, 1H, H-51), 6.86–6.97 (m,
3H, Ar-H and H-3), 7.02 (d, J = 8.8 Hz, 2H, Ar-H), 7.18–7.21 (m, 4H, Ar-H), 7.54 (d, J = 8.4 Hz, 2H,
Ar-H), 7.82–7.95 (m, 3H, Ar-H and H-6), 8.14 (d, J = 1.6 Hz, 1H, H-8), 8.55 (d, J = 6.8 Hz, 1H, H-2), 8.83
(d, J = 9.0 Hz, 1H, H-5), 11.06 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.5 (CH2), 55.6
(OCH3), 63.2, 101.4, 114.9, 115.0, 116.9 (C), 120.6, 122.7 (C), 125.4, 126.4, 127.6, 127.7, 127.8, 129.2, 131.2
(C), 134.3 (C), 138.1 (C), 138.6 (C), 140.6 (C), 143.3 (C), 145.0, 147.8 (C), 154.3 (C), 159.1 (C). MS (70 eV)
m/z (%): 538 (100, M+). Anal. Calcd. For C31H24Cl2N4O: C, 69.02; H, 4.48; N, 10.39. Found: C, 69.08;
H, 4.44; N, 10.51.
7-Chloro-N-(4-(1-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-
amine (25). Yellow solid; 63% yield; mp: 218–220 ˝C. FTIR (KBr) υ(cm´1): 3434 (NH), 2969 (=C-H) and
1595 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.22 (dd, J = 17.6, 6.9 Hz, 1H, H-41a),
3.64 (s, 3H, OCH3), 3.72 (s, 6H, 2 ˆ OCH3), 3.96 (dd, J = 17.6, 12.1 Hz, 1H, H-41b), 5.42 (dd, J = 12.1,
6.9 Hz, 1H, H-51), 6.95 (d, J = 7.0 Hz, 1H, H-3), 7.05 (d, J = 9.0 Hz, 2H, Ar-H), 7.21–7.29 (m, 4H, Ar-H),
7.55 (d, J = 8.6 Hz, 2H, Ar-H), 7.86 (dd, J = 9.0, 1.8 Hz, 1H, H-6), 7.91 (d, J = 8.6 Hz, 2H, Ar-H), 8.15 (d,
J = 1.8 Hz, 1H, H-8), 8.55 (d, J = 7.0 Hz, 1H, H-2), 8.85 (d, J = 9.0 Hz, 1H, H-5), 11.08 (br s, 1H, NH).
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13C-NMR (100 MHz, DMSO-d6) δ ppm 43.7 (CH2), 56.4 (2 ˆ OCH3), 60.5 (OCH3), 64.4, 101.3, 103.4,
114.8, 115.1, 116.9 (C), 122.8 (C), 123.0 (C), 125.3, 126.5, 127.0, 127.7, 129.2, 131.1 (C), 137.2 (C), 138.2 (C),
140.2 (C), 141.0 (C), 143.8 (C), 144.7, 145.4 (C), 148.2 (C), 153.9 (C). MS (70 eV) m/z (%): 598 (7, M+), 420
(100), 294 (43), 281 (21), 166 (20), 125 (39). Anal. Calcd. For C33H28Cl2N4O3: C, 66.11; H, 4.71; N, 9.35.
Found: C, 66.13; H, 4.94; N, 9.36.
7-Chloro-N-(4-(1-(4-chlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (26).
Yellow solid; 70% yield; mp: 296–298 ˝C. FTIR (KBr) υ(cm´1): 3424 (NH), 2974 (=C-H), 1614 and 1590
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 2.26 (s, 3H, CH3), 3.15 (dd, J = 17.6, 5.9 Hz, 1H,
H-41a), 3.95 (dd, J = 17.6, 12.3 Hz, 1H, H-41b), 5.51 (dd, J = 12.3, 5.9 Hz, 1H, H-51), 6.94 (d, J = 6.8 Hz,
1H, H-3), 7.01 (d, J = 9.2 Hz, 2H, Ar-H), 7.12–7.24 (m, 6H, Ar-H), 7.55 (d, J = 8.6 Hz, 2H, Ar-H), 7.85 (dd,
J = 9.1, 2.0 Hz, 1H, H-6), 7.90 (d, J = 8.6 Hz, 2H, Ar-H), 8.18 (d, J = 2.0 Hz, 1H, H-8), 8.55 (d, J = 6.8 Hz,
1H, H-2), 8.89 (d, J = 9.1 Hz, 1H, H-5), 11.05 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 21.2
(CH3), 43.5 (CH2), 63.5, 101.3, 114.9, 116.9 (C), 120.3, 122.8 (C), 125.4, 126.3, 126.6, 127.6, 127.7, 129.2,
130.1, 131.2 (C), 137.3 (C), 138.1 (C), 138.6 (C), 139.5 (C), 140.4 (C), 143.3 (C), 144.5, 147.8 (C), 154.4 (C).
MS (70 eV) m/z (%): 522 (100, M+), 279 (20), 243 (13), 125 (38). Anal. Calcd. For C31H24Cl2N4: C, 71.13;
H, 4.62; N, 10.70. Found: C, 71.09; H, 4.56; N, 10.71.
3.2.4. General Procedure for the Preparation of Compounds 27–32
A mixture of chalcone 7–12 (0.11 mmol), phenylhydrazine 13 (0.22 mmol), glacial acetic acid (0.8
mL, molar excess) and EtOH (8 mL) was heated under reflux for 3 h until complete consumption of the
chalcone (monitored by TLC). The product was observed as a precipitate and was filtered and washed
with EtOH/H2O (1:0.5) mixture. No further purification was required.
N-(3-(5-(4-Bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine (27).
Yellow solid; 83% yield; mp: 228–231 ˝C. FTIR (KBr) υ(cm´1): 3354 (NH), 3053 (=C-H), 1602 and 1569
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.13 (dd, J = 17.4, 6.1 Hz, 1H, H-41a), 3.93 (dd,
J = 17.4, 12.1 Hz, 1H, H-41b), 5.52 (dd, J = 12.1, 6.1 Hz, 1H, H-51), 6.73 (t, J = 7.6 Hz, 1H, Ar-H), 6.98–7.03
(m, 3H, Ar-H and H-3), 7.16 (t, J = 7.6 Hz, 2H, Ar-H), 7.25 (d, J = 8.3 Hz, 2H, Ar-H), 7.39–7.41 (m, 1H,
Ar-H), 7.47 (d, J = 4.5 Hz, 2H, Ar-H), 7.54 (d, J = 8.3 Hz, 2H, Ar-H), 7.59 (dd, J = 9.0, 1.7 Hz, 1H, H-6),
7.76 (s, 1H, Ar-H), 7.91 (d, J = 1.7 Hz, 1H, H-8), 8.44 (d, J = 9.0 Hz, 1H, H-5), 8.49 (d, J = 5.0 Hz, 1H,
H-2), 9.19 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.2 (CH2), 63.0, 79.7 (C), 102.6, 113.5,
119.4, 119.9, 121.0 (C), 122.0, 123.1, 124.9, 125.6, 128.2, 128.7, 129.5, 130.2, 132.4, 134.0 (C), 134.5 (C),
135.9 (C), 141.1 (C), 144.4 (C), 147.5 (C), 148.3 (C), 150.1 (C), 152.5. MS (70 eV) m/z (%): 552 (100, M+),
397 (62), 280 (40), 218 (24), 91 (33), 77 (45). Anal. Calcd. For C30H22BrClN4: C, 65.05; H, 4.00; N, 10.12.
Found: C, 65.05; H, 4.11; N, 10.25.
7-Chloro-N-(3-(5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (28).
Yellow solid; 81% yield; mp: 187–188 ˝C. FTIR (KBr) υ(cm´1): 3263 (NH), 3056 (=C-H), 1597 and 1569
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.13 (dd, J = 17.6, 6.0 Hz, 1H, H-41a), 3.94 (dd,
J = 17.6, 12.1 Hz, 1H, H-41b), 5.55 (dd, J = 12.1, 6.0 Hz, 1H, H-51), 6.73 (t, J = 7.2 Hz, 1H, Ar-H), 6.97–6.99
(m, 3H, Ar-H and H-3), 7.12–7.20 (m, 2H, Ar-H), 7.32 (d, J = 8.3 Hz, 2H, Ar-H), 7.37–7.43 (m, 3H, Ar-H),
7.48 (d, J = 4.8 Hz, 2H, Ar-H), 7.59 (dd, J = 8.8, 1.6 Hz, 1H, H-6), 7.77 (s, 1H, Ar-H), 7.91 (d, J = 1.6 Hz,
1H, H-8), 8.44 (d, J = 8.8 Hz, 1H, H-5), 8.50 (d, J = 5.3 Hz, 1H, H-2), 9.19 (br s, 1H, NH). 13C-NMR
(100 MHz, DMSO-d6) δ ppm 42.7 (CH2), 62.5, 76.5 (C), 102.1, 113.0, 118.9, 119.4, 121.5 (C), 122.6, 124.5,
125.1, 127.7, 127.9, 129.0, 129.8, 132.8, 133.5 (C), 134.0 (C), 135.9 (C), 140.6 (C), 143.9 (C), 147.8 (C), 148.5,
148.9 (C), 149.6 (C), 152.1. MS (70 eV) m/z (%): 508 (100, M+), 397 (45), 296 (36), 281 (28), 218 (59), 43
(51). Anal. Calcd. For C30H22Cl2N4: C, 70.73; H, 4.35; N, 11.00. Found: C, 70.77; H, 4.39; N, 10.91.
7-Chloro-N-(3-(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (29). Yellow solid; 73%
yield; mp: 202–203 ˝C. FTIR (KBr) υ(cm´1): 3342 (NH), 3051 (=C-H), 1598 and 1567 (C=N and C=C).
1H-NMR (400 MHz, DMSO-d6) δ ppm 3.12 (dd, J = 17.5, 6.3 Hz, 1H, H-41a), 3.94 (dd, J = 17.5, 12.2 Hz,
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1H, H-41b), 5.50 (dd, J = 12.2, 6.3 Hz, 1H, H-51), 6.71 (t, J = 7.3 Hz, 1H, Ar-H), 6.97–7.03 (m, 3H, Ar-H
and H-3), 7.10–7.17 (m, 2H, Ar-H), 7.23–7.41 (m, 6H, Ar-H), 7.45–7.49 (m, 2H, Ar-H), 7.59 (dd, J = 9.0,
2.0 Hz, 1H, H-6), 7.78 (s, 1H, Ar-H), 7.91 (d, J = 2.0 Hz, 1H, H-8), 8.45 (d, J = 9.0 Hz, 1H, H-5), 8.49 (d,
J = 5.3 Hz, 1H, H-2), 9.19 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.0 (CH2), 63.2, 99.5
(C), 102.1, 113.0, 118.4 (C), 119.4, 121.5, 122.6, 124.5, 125.1, 125.3, 125.8, 127.6, 128.9, 129.0, 129.1, 129.7,
133.6 (C), 134.0 (C), 142.4 (C), 144.1 (C), 146.8 (C), 147.9 (C), 149.5 (C), 152.0. MS (70 eV) m/z (%): 474
(100, M+), 397 (77), 280 (21), 218 (17), 91 (35), 77 (40). Anal. Calcd. For C30H23ClN4: C, 75.86; H, 4.88; N,
11.80. Found: C, 75.78; H, 4.92; N, 11.85.
7-Chloro-N-(3-(5-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (30).
Yellow solid; 68% yield; mp: 189–191 ˝C. FTIR (KBr) υ(cm´1): 3274 (NH), 3057 (=C-H), 1620 and 1599
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6): δ ppm = 3.09 (dd, J = 17.3, 6.2 Hz, 1H, H-41a), 3.71 (s,
3H, OCH3), 3.90 (dd, J = 17.3, 12.2 Hz, 1H, H-41b), 5.45 (dd, J = 12.2, 6.2 Hz, 1H, H-51), 6.71 (t, J = 7.3 Hz,
1H, Ar-H), 6.89 (d, J = 8.7 Hz, 2H, Ar-H), 6.97–7.03 (m, 3H, Ar-H and H-3), 7.11–7.17 (m, 2H, Ar-H), 7.21
(d, J = 8.7 Hz, 2H, Ar-H), 7.39–7.41 (m, 1H, Ar-H), 7.45–7.48 (m, 2H, Ar-H), 7.57–7.60 (m, 1H, Ar-H),
7.77 (s, 1H, Ar-H), 7.91 (d, J = 2.0 Hz, 1H, H-8), 8.45 (d, J = 9.0 Hz, 1H, H-5), 8.49 (d, J = 5.3 Hz, 1H,
H-2), 9.19 (s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6): δ ppm = 43.0 (CH2), 55.0 (OCH3), 62.8, 102.1,
113.1, 114.3, 118.7, 119.3, 121.5, 122.5, 124.4, 125.0, 127.1, 127.7, 128.8, 129.7, 133.7 (C), 134.0 (C), 134.3
(C), 135.9 (C), 140.6 (C), 144.1 (C), 146.8 (C), 147.8 (C), 149.6 (C), 152.1, 158.5 (C). MS (70 eV) m/z (%):
504 (100, M+), 397 (57), 280 (25), 218 (21), 77 (29). Anal. Calcd. For C31H25ClN4O: C, 73.73; H, 4.99; N,
11.09. Found: C, 73.67; H, 4.89; N, 11.16.
7-Chloro-N-(3-(1-phenyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine
(31). Yellow solid; 65% yield; mp: 183–186 ˝C. FTIR (KBr) υ(cm´1): 3285 (NH), 3028 (=C-H), 1665
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.16 (dd, J = 17.5, 7.3 Hz, 1H, H-41a), 3.72 (s,
3H, OCH3), 3.86 (s, 6H, 2 ˆ OCH3), It is not observed (dd, 1H, H-41b), 5.37 (dd, J = 12.2, 7.3 Hz, 1H,
H-51), 6.72–6.77 (m, 1H, Ar-H), 6.98–7.07 (m, 3H, Ar-H), 7.10–7.21 (m, 4H, Ar-H), 7.36–7.42 (m, 1H,
Ar-H), 7.45–7.51 (m, 2H, Ar-H), 7.59 (dd, J = 9.1, 2.2 Hz, 1H, H-6), 7.78 (s, 1H, Ar-H), 7.92 (d, J = 2.2 Hz,
1H, H-8), 8.40–8.54 (m, 2H, H-5 and H-2), 9.62 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm
43.6 (CH2), 56.3 (2 x OCH3), 60.4 (OCH3), 64.4, 100.0 (C), 102.5, 113.7, 119.3 (C), 119.4, 119.8, 121.0 (C),
122.0, 123.1, 125.0, 125.6, 128.1, 129.4, 129.5, 130.3, 134.1 (C), 134.5 (C), 137.0 (C), 138.8 (C), 145.1 (C),
147.7 (C), 148.3 (C), 150.1 (C), 152.5. MS (70 eV) m/z (%): 564 (100, M+), 397 (65), 279 (14), 91 (37), 77
(14). Anal. Calcd. For C33H29ClN4O3: C, 70.14; H, 5.17; N, 9.92. Found: C, 69.97; H, 5.25; N, 10.03.
7-Chloro-N-(3-(1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (32). Yellow solid;
72% yield; mp: 210–212 ˝C. FTIR (KBr) υ(cm´1): 3187 (NH), 3058 (=C-H), 1617 and 1594 (C=N and
C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 2.30 (s, 3H, CH3), 3.11 (dd, J = 17.4, 6.2 Hz, 1H, H-41a),
3.91 (dd, J = 17.4, 12.2 Hz, 1H, H-41b), 5.48 (dd, J = 12.2, 6.2 Hz, 1H, H-51), 6.75 (t, J = 7.1 Hz, 1H, Ar-H),
6.83 (d, J = 7.0 Hz, 1H, H-3), 7.16–7.24 (m, 2H, Ar-H), 7.24–7.29 (m, 2H, Ar-H), 7.41 (d, J = 7.9 Hz, 2H,
Ar-H), 7.57 (d, J = 7.9 Hz, 2H, Ar-H), 7.77–7.82 (m, 1H, Ar-H), 7.85 (d, J = 8.3 Hz, 2H, Ar-H), 7.87 (dd,
J = 9.2, 2.2 Hz, 1H, H-6), 7.90 (s, 1H, Ar-H), 8.21 (d, J = 2.2 Hz, 1H, H-8), 8.52 (d, J = 7.0 Hz, 1H, H-2),
8.92 (d, J = 9.2 Hz, 1H, H-5), 9.19 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 13.4 (CH3),
43.0 (CH2), 63.0, 100.9, 113.4, 114.5, 119.6, 119.7, 121.5, 122.4, 124.7, 125.0, 126.8, 127.8, 129.4, 130.4,
133.7 (C), 135.9 (C), 137.6 (C), 138.9 (C), 139.6 (C), 139.8 (C), 141.7 (C), 143.8, 144.1 (C), 146.3 (C), 155.5
(C). MS (70 eV) m/z (%): 488 (78, M+), 490 (100), 397 (52), 280 (23), 218 (19), 77 (14). Anal. Calcd. For
C31H25ClN4: C, 76.14; H, 5.15; N, 11.46. Found: C, 76.10; H, 5.15; N, 11.52.
3.2.5. General Procedure for the Preparation of Compounds 33–38
A mixture of the corresponding 3-(7-chloroquinolin-4-yl)amino chalcone 7–12 (0.11 mmol),
4-chlorophenylhydrazine hydrochloride 14 (0.22 mmol), glacial acetic acid (0.2 mL, molar excess), and
EtOH (8 mL) was heated under reflux for 8 h, until the reaction is complete and the product precipitated.
Afterward, the solid product was filtered, washed with water, and recrystallized from ethanol.
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N-(3-(5-(4-Bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine
(33). Yellow solid; 75% yield; mp: 201–203 ˝C. FTIR (KBr) υ(cm´1): 3166 (NH), 3049 (=C-H), 1618 and
1595 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.18 (dd, J = 17.6, 6.0 Hz, 1H, H-41a), 3.96
(dd, J = 17.6, 12.4 Hz, 1H, H-41b), 5.59 (dd, J = 12.4, 6.0 Hz, 1H, H-51), 6.86 (d, J = 6.9 Hz, 1H, H-3), 6.99
(d, J = 8.8 Hz, 2H, Ar-H), 7.17–7.26 (m, 4H, Ar-H), 7.51 (d, J = 7.8 Hz, 1H, Ar-H), 7.55 (d, J = 8.3 Hz, 2H,
Ar-H), 7.62 (t, J = 7.8 Hz, 1H, Ar-H), 7.74 (d, J = 7.8 Hz, 1H, Ar-H), 7.85–7.92 (m, 2H, Ar-H and H-6),
8.21 (d, J = 2.0 Hz, 1H, H-8), 8.53 (d, J = 6.9 Hz, 1H, H-2), 8.91 (d, J = 9.0 Hz, 1H, H-5), 11.28 (br s, 1H,
NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 42.8 (CH2), 62.4, 100.5, 114.5, 116.0 (C), 119.3, 122.4, 122.6
(C), 124.9, 125.6, 126.2, 127.4, 127.8, 128.8, 129.1, 130.3, 132.1 (C), 133.8 (C), 137.5 (C), 138.4 (C), 139.2 (C),
140.7 (C), 142.5 (C), 143.5, 147.3 (C), 154.8 (C). MS (70 eV) m/z (%): 588 (100), 586 (84, M+), 431 (52), 279
(32), 243 (26), 218 (20), 125 (68), 111 (25), 90 (34). Anal. Calcd. For C30H21BrCl2N4: C, 61.25; H, 3.60; N,
9.52. Found: C, 61.32; H, 3.76; N, 10.01.
N-(3-(1,5-bis(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-7-chloroquinolin-4-amine (34). Yellow
solid; 71% yield; mp: 206–207 ˝C. FTIR (KBr) υ(cm´1): 3160 (NH), 3049 (=C-H), 1617 and 1588 (C=N
and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.17 (dd, J = 17.6, 6.0 Hz, 1H, H-41a), 3.96 (dd, J = 17.6,
12.2 Hz, 1H, H-41b), 5.60 (dd, J = 12.2, 6.0 Hz, 1H, H-51), 6.85 (d, J = 7.0 Hz, 1H, H-3), 6.98 (d, J = 9.0 Hz,
2H, Ar-H), 7.19 (d, J = 9.0 Hz, 2H, Ar-H), 7.29 (d, J = 8.5 Hz, 2H, Ar-H), 7.41 (d, J = 8.5 Hz, 2H, Ar-H),
7.50 (dd, J = 8.0, 0.9 Hz, 1H, Ar-H), 7.61 (t, J = 8.0 Hz, 1H, Ar-H), 7.73 (d, J = 8.0 Hz, 1H, Ar-H), 7.84–7.91
(m, 2H, Ar-H and H-6), 8.21 (d, J = 2.0 Hz, 1H, H-8), 8.53 (d, J = 7.0 Hz, 1H, H-2), 8.93 (d, J = 9.0 Hz, 1H,
H-5), 11.30 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 41.2 (CH2), 49.8, 100.0 (C), 100.6,
116.5 (C), 119.8, 120.4 (C), 125.2, 126.6, 128.0, 128.1, 130.5, 130.7, 131.0, 131.2, 131.4, 132.4, 137.6 (C),
137.7 (C), 138.1 (C), 138.9 (C), 139.1 (C), 139.6 (C), 144.1, 155.4 (C), 198.2 (C). MS (70 eV) m/z (%): 542
(100, M+), 431 (49), 279 (26), 125 (18), 90 (13). Anal. Calcd. For C30H21Cl3N4: C, 66.25; H, 3.89; N, 10.30.
Found: C, 66.27; H, 3.95; N, 10.36.
7-Chloro-N-(3-(1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (35).
Yellow solid; 61% yield; mp: 245–246 ˝C. FTIR (KBr) υ(cm´1): 3354 (NH), 3056 (=C-H), 1615 and 1591
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.17 (dd, J = 17.6, 6.1 Hz, 1H, H-41a), 3.97 (dd,
J = 17.6, 12.3 Hz, 1H, H-41b), 5.58 (dd, J = 12.3, 6.1 Hz, 1H, H-51), 6.88 (d, J = 6.9 Hz, 1H, H-3), 7.00 (d,
J = 9.0 Hz, 2H, Ar-H), 7.19 (d, J = 9.0 Hz, 2H, Ar-H), 7.28 (m, 3H, Ar-H), 7.33–7.39 (m, 2H, Ar-H), 7.50
(dd, J = 8.0, 0.8 Hz, 1H, Ar-H), 7.61 (t, J = 7.8 Hz, 1H, Ar-H), 7.72 (d, J = 7.8 Hz, 1H, Ar-H), 7.86 (dd,
J = 9.1, 2.0 Hz, 1H, H-6), 7.90 (s, 1H, Ar-H), 8.18 (d, J = 2.0 Hz, 1H, H-8), 8.54 (d, J = 6.9 Hz, 1H, H-2),
8.89 (d, J = 9.1 Hz, 1H, H-5), 11.14 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.5 (CH2),
63.6, 101.1, 114.9, 116.7 (C), 120.5, 122.6, 122.9 (C), 125.1, 125.8, 126.3, 126.6, 127.7, 128.1, 129.2, 129.6,
130.8, 134.3 (C), 138.3 (C), 138.5 (C), 140.5 (C), 142.3 (C), 143.2 (C), 144.8, 147.7 (C), 154.7 (C). MS (70 eV)
m/z (%): 508 (100, M+), 431 (28), 279 (16), 236 (24), 125 (33), 111 (26), 97 (19), 83 (22), 57 (35), 43 (27).
Anal. Calcd. For C30H22Cl2N4: C, 70.73; H, 4.35; N, 11.00. Found: C, 70.64; H, 4.38; N, 11.12.
7-Chloro-N-(3-(1-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine
(36). Yellow solid; 47% yield; mp: 216–218 ˝C. FTIR (KBr) υ(cm´1): 3189 (NH), 3060 (=C-H), 1617 and
1594 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.20 (dd, J = 17.6, 7.0 Hz, 1H, H-41a),
3.71 (s, 3H, OCH3), 3.95 (dd, J = 17.6, 12.3 Hz, 1H, H-41b), 5.43 (dd, J = 12.3, 7.0 Hz, 1H, H-51), 6.89 (d,
J = 7.0 Hz, 1H, H-3), 6.98 (d, J = 9.0 Hz, 2H, Ar-H), 7.04 (d, J = 9.0 Hz, 2H, Ar-H), 7.22 (d, J = 8.8 Hz, 2H,
Ar-H), 7.35 (d, J = 8.8 Hz, 2H, Ar-H), 7.51 (d, J = 8.0 Hz, 1H, Ar-H), 7.64 (t, J = 8.0 Hz, 1H, Ar-H), 7.76 (d,
J = 8.0 Hz, 1H, Ar-H), 7.85 - 7.92 (m, 2H, Ar-H and H-6), 8.14 (d, J = 2.0 Hz, 1H, H-8), 8.53 (d, J = 7.0 Hz,
1H, H-2), 8.85 (d, J = 9.0 Hz, 1H, H-5), 11.20 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.4
(CH2), 55.0 (OCH3), 63.8, 100.5, 114.3, 116.1 (C), 119.6, 121.8, 122.4 (C), 124.3, 124.4, 125.9, 127.3, 128.7,
129.2, 129.6, 130.0, 134.3 (C), 137.1 (C), 138.3 (C), 138.5 (C), 139.5 (C), 140.4 (C), 140.9 (C), 143.8, 144.7
(C), 154.7 (C). MS (70 eV) m/z (%): 538 (1, M+), 419 (100), 280 (22), 243 (18), 218 (54), 126 (24), 99 (24).
Anal. Calcd. For C31H24Cl2N4O: C, 69.02; H, 4.48; N, 10.39. Found: C, 69.11; H, 4.55; N, 10.41.
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7-Chloro-N-(3-(1-(4-chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-
amine (37). Yellow solid; 53% yield; mp: 200–201 ˝C. FTIR (KBr) υ(cm´1): 3204 (NH), 3053 (=C-H),
1615 and 1589 (C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 3.08–3.19 (m, 1H, H-41a), 3.71 (s,
3H, OCH3), 3.79 (s, 6H, 2 ˆ OCH3), 3.92 (dd, J = 17.7, 12.2 Hz, 1H, H-41b), 5.51 (dd, J = 12.2, 6.0 Hz,
1H, H-51), 6.82–6.93 (m, 1H, H-3), 6.99 (m, 2H, Ar-H), 7.17–7.20 (m, 4H, Ar-H), 7.51 (d, J = 7.8 Hz, 1H,
Ar-H), 7.57–7.72 (m, 1H, Ar-H), 7.83–7.93 (m, 3H, Ar-H), 8.15 (d, J = 9.2 Hz, 1H, H-6), 8.54 (d, J = 6.8 Hz,
1H, H-2), 8.85 (d, J = 9.2 Hz, 1H, H-5), 11.19 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6) δ ppm 43.5
(CH2), 56.4 (2 ˆ OCH3), 60.5 (OCH3), 64.3, 100.0 (C), 101.0, 103.4, 114.1, 114.5, 115.1, 116.4 (C), 119.7,
122.8, 123.2 (C), 126.4, 128.1, 129.0, 129.2, 134.4 (C), 136.4 (C), 137.1 (C), 137.2 (C), 138.1 (C), 139.4 (C),
143.9, 148.1 (C), 153.8 (C), 155.5 (C). MS (70 eV) m/z (%): 598 (100, M+), 431 (59), 279 (16), 125 (39), 90
(10). Anal. Calcd. For C33H28Cl2N4O3: C, 66.11; H, 4.71; N, 9.35. Found: C, 66.15; H, 4.78; N, 9.45.
7-Chloro-N-(3-(1-(4-chlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)quinolin-4-amine (38).
Yellow solid; 60% yield; mp: 207–208 ˝C. FTIR (KBr) υ(cm´1): 3174 (NH), 3050 (=C-H), 1618 and 1590
(C=N and C=C). 1H-NMR (400 MHz, DMSO-d6) δ ppm 2.25 (s, 3H, CH3), 3.13 (dd, J = 17.6, 6.0 Hz, 1H,
H-41a), 3.94 (dd, J = 17.6, 12.3 Hz, 1H, H-41b), 5.52 (dd, J = 12.3, 6.0 Hz, 1H, H-51), 6.86 (d, J = 6.9 Hz,
1H, H-3), 6.99 (d, J = 8.8 Hz, 2H, Ar-H), 7.11–7.21 (m, 6H, Ar-H), 7.50 (d, J = 7.9 Hz, 1H, Ar-H), 7.62 (t,
J = 7.9 Hz, 1H, Ar-H), 7.73 (d, J = 7.9 Hz, 1H, Ar-H), 7.84–7.92 (m, 2H, Ar-H and H-6), 8.20 (s, 1H, H-8),
8.53 (d, J = 6.9 Hz, 1H, H-2), 8.91 (d, J = 9.0 Hz, 1H, H-5), 11.27 (br s, 1H, NH). 13C-NMR (100 MHz,
DMSO-d6) δ ppm 20.7 (CH3), 43.0 (CH2), 63.0, 100.5, 114.5, 116.0 (C), 119.3, 122.3, 122.4 (C), 124.9, 125.5,
125.8, 126.2, 127.4, 128.7, 129.6, 130.4, 134.0 (C), 136.8 (C), 137.5 (C), 138.4 (C), 138.9 (C), 139.1 (C), 142.7
(C), 143.5, 147.2 (C), 154.9 (C). MS (70 eV) m/z (%): 522 (100, M+), 431 (24), 279 (16), 125 (30), 91 (12), 44
(14). Anal. Calcd. For C31H24Cl2N4: C, 71.13; H, 4.62; N, 10.70. Found: C, 71.18; H, 4.74; N, 10.80.
3.3. Antiproliferative Activity
The human tumor cell lines of the cancer screening panel were grown in an RPMI-1640 medium
containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells
were inoculated into 96-well microtiter plates. After cell inoculation, the microtiter plates were
incubated at 37 ˝C, 5% CO2, 95% air, and 100% relative humidity for 24 h prior to the addition
of the tested compounds. After 24 h, two plates of each cell line were fixed in situ with TCA, to
represent a measurement of the cell population for each cell line at the time of sample addition (Tz).
The samples were solubilized in dimethyl sulfoxide (DMSO) at 400-fold the desired final maximum
test concentration and stored frozen prior to use. At the time of compound addition, an aliquot of
frozen concentrate was thawed and diluted to twice the desired final maximum test concentration with
complete medium containing 50 µg/mL gentamicin. An additional four 10-fold or 12 log serial dilutions
were made to provide a total of five drug concentrations plus the control. Aliquots of 100 µL of these
different sample dilutions were added to the appropriate microtiter wells already containing 100 µL
of medium, resulting in the required final sample concentrations [19]. After the tested compounds
were added, the plates were incubated for an additional 48 h at 37 ˝C, 5% CO2, 95% air, and 100%
relative humidity. For adherent cells, the assay was terminated by the addition of cold TCA. Cells were
fixed in situ by the gentle addition of 50 µL of cold 50% (w/v) TCA (final concentration, 10% TCA)
and incubated for 60 min at 4 ˝C. The supernatant was discarded, and plates were washed five times
with tap water and air dried. Sulforhodamine B (SRB) solution (100 µL) at 0.4% (w/v) in 1% acetic acid
was added to each well, and plates were incubated for 10 min at room temperature. After staining,
unbound dye was removed by washing five times with 1% acetic acid and the plates were air dried.
Bound stain was subsequently solubilized with 10 mM trizma base, and the absorbance was read on an
automated plate reader at a wavelength of 515 nm. Using the seven absorbance measurements [time
zero (Tz), control growth in the absence of drug (C), and test growth in the presence of drug at the five
concentration levels (Ti)], the percentage growth was calculated at each of the drug concentrations
levels. Percentage growth inhibition was calculated as: [(Ti ´ TZ)/(C ´ TZ)] ˆ 100 for concentrations
for which Ti > Tz, and [(Ti ´ TZ)/TZ] ˆ 100 for concentrations for which Ti < Tz. Two dose-response
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parameters were calculated for each compound. Growth inhibition of 50% (GI50) was calculated from
[(Ti ´ TZ)/(C ´ TZ)] ˆ 100 = 50, which is the drug concentration resulting in a 50% lower net protein
increase in the treated cells (measured by SRB staining) as compared to the net protein increase seen
in the control cells and the LC50 (concentration of drug resulting in a 50% reduction in the measured
protein at the end of the drug treatment as compared to that at the beginning), indicating a net loss
of cells; calculated from [(Ti ´ TZ)/TZ] ˆ 100 = ´50). Values were calculated for each of these two
parameters if the level of activity is reached; however, if the effect was not reached or was exceeded, the
value for that parameter was expressed as greater or less than the maximum or minimum concentration
tested [19–21].
3.4. Antifungal Activity
3.4.1. Microorganisms and Media
For the antifungal evaluation, strains from the American Type Culture Collection (ATCC,
Rockville, MD, USA), C. albicans ATCC 10231 and C. neoformans ATCC 32264, were used. Strains
were grown on Sabouraud-chloramphenicol agar slants for 48 h at 30 ˝C, maintained on slopes of
Sabouraud-dextrose agar (SDA, Oxoid, Basingstoke Hampshire, UK), and sub-cultured every 15 days
to prevent pleomorphic transformations. Inocula were obtained according to reported procedures [26]
and adjusted to 1–5 ˆ 103 cells with colony-forming units (CFU)/mL.
3.4.2. Fungal Growth Inhibition Percentage Determination
Yeast broth microdilution technique M27-A3 of CLSI [26] was performed in 96-well microplates.
For the assay, compound test-wells (CTWs) were prepared with stock solutions of each compound
in DMSO (maximum concentration ď1%), diluted with RPMI-1640 to final concentrations of
250–3.9 µg/mL. An inoculum suspension (100 µL) was added to each well (final volume in the
well = 200 µL). A growth control well (GCW) (containing medium, inoculum, and the same amount
of DMSO used in a CTW, but compound-free) and a sterility control well (SCW) (sample, medium,
and sterile water instead of inoculum) were included for each fungus tested. Microtiter trays were
incubated in a moist, dark chamber at 30 ˝C for 48 h for both yeasts. Microplates were read in a VERSA
Max microplate reader (Molecular Devices, Sunnyvale, CA, USA). Amphotericin B (Sigma-Aldrich,
St. Louis, MO, USA) was used as a positive control. Tests were performed in triplicate. Reduction of
growth for each compound concentration was calculated as follows: % of inhibition = 100 ´ (OD 405
CTW ´ OD 405 SCW)/(OD 405 GCW ´ OD 405 SCW). The means ˘ SD (standard deviations) were
used for constructing the dose–response curves. Representing % inhibition vs. concentration of each
compound. Dose–response curves were constructed with SigmaPlot 11.0 software (Systat Software
Inc., San Jose, CA, USA).
3.4.3. MIC100, MIC80, and MIC50 Determinations
Three endpoints were defined from the dose–response curves. Minimum Inhibitory concentration
(MIC) resulting in total fungal growth inhibition was named MIC100 while MIC80 and MIC50 were
defined as the minimum concentration that inhibits 80% or 50% of the fungal growth, respectively.
3.4.4. Statistical Analysis
Comparisons of activities were statistically analyzed by applying the Student t-test. Values of
p < 0.05 were considered to be significant.
4. Conclusions
In this article, we report the synthesis of a novel series of N-aryl-substituted pyrazolines under
mild reaction conditions, easy work-up, short reaction times, and good yields. The antiproliferative
evaluation data against 58 cancer cell lines revealed that compounds with an m-substitution in ring A
and EDG (4-OCH3 and 3,4,5-tri-OCH3) in ring C exhibited the highest activity, with GI50 values lower
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than 1.0 µM for several of the cell lines tested (Compounds 25, 30, 31, 36, and 37). Furthermore, these
compounds displayed higher cytostatic activity against several cell lines compared to the standard
drug, adriamycin. Regarding the antifungal activity, compounds 15–38 showed activity against C.
albicans and C. neoformans with varied MIC50 values between <3.9 and 250 µg/mL. However, among
the different sub-groups, the compounds in series (ii) showed better activity than those in group (i)
against both fungi, These results indicate that the position of the azole moiety does play a role in
the antifungal activity and that compounds with this moiety in the m-position are better antifungal
candidates than those with the azole moiety in the p-position. Within the two sub-groups in series (ii),
the best activity was displayed by compounds with a p-Cl moiety in the aryl ring D. It could be showed
that C. neoformans had higher sensitivity to these compounds than the other fungus tested (C. albicans).
Compound 36 exhibited the highest antifungal properties, becoming an interesting candidate for new
antifungal studies.
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